![Scinai Immunotherapeutics Ltd](/common/images/company/N_SCNI.png)
BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic ... BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic. Show more
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model PR Newswire JERUSALEM, July 15, 2024 JERUSALEM, July 15, 2024 /PRNewswire/...
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity PR Newswire JERUSALEM...
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements PR Newswire JERUSALEM, July 3, 2024 JERUSALEM, July 3, 2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.